Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

In Depth 3 Mar 2020

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

In Depth 25 Feb 2020

Biotechnology Is Changing How We Make Clothes

The fashion industry is seeing the beginnings of a biotechnological revolution: using biology to make clothing to make textiles better and more sustainable. Biotechnology already plays an important role in the textile industry. Enzymes are used routinely to wash and bleach textiles, to give jeans a denim look or to prevent wool from shrinking. A […]

February 25, 2020 - 7 minutesmins - By Clara Rodríguez Fernández

Expert Advice 27 Jan 2020

Five Reasons Why Biotech Startups Fail: How to Avoid Them

Biotech startups are a high-risk venture and many do not reach the final line. Experts explain what the most common reasons for failure are and what can be done to avoid them. You might have heard that only 10% of startups make it. Well, biotech startups can have it even harder. Unlike the typical tech […]

January 27, 2020 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Jan 2020

Broad Institute Loses Appeal on European CRISPR Patent

A decision from the Boards of Appeal at the European Patent Office has revoked the claim of the Broad Institute to general patents on CRISPR/Cas9 gene editing technology, strengthening the position of its opponent UC Berkeley in Europe. The Broad Institute in Cambridge, US, is one of the main contenders in the ongoing battle for […]

January 24, 2020 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jan 2020

German Biotech Raises €11M to Regenerate Liver Damage

Biotech company HepaRegeniX has raised a Series B round that will allow its first candidate drug for liver disease to enter clinical trials later this year. Based in Tübingen, Germany, HepaRegenix was founded in 2017 with a €9M Series A round. The same investors are now taking part in a Series B round […]

January 21, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 14 Jan 2020

What’s the Secret to Making Returns in Industrial Biotech?

As industrial biotech starts gaining more and more traction, investors need to change their mindset in order to start making returns in this promising field. Microorganisms have been helping us make food and drink since ancient times. Thanks to the industrial biotech revolution, these microbes could soon be responsible for manufacturing anything from clothing to […]

January 14, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2020

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […]

January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2019

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals. The fundraising was co-led by food tech investor Agronomics and M Ventures, the corporate venture capital arm of Merck. CPT Capital, an investor in alternative proteins, […]

December 20, 2019 - 1 minutemin - By Clara Rodríguez Fernández

More News! 18 Dec 2019

French Biotech Raises €20M to Treat Cannabis Addiction Without Side Effects

Bordeaux-based Aelis Farma will use €20M in fresh funding to develop a new treatment for cannabis addiction and cannabis-induced psychosis, as well as a therapy for cognitive deficits in Down’s syndrome. The funding consists of €11M from a financing round coming mostly from regional investors, in addition to €9M raised through research grants. The […]

December 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Futura medical erectile dysfunction medication

More News! 10 Dec 2019

After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction

The strong placebo effect seen in Futura Medical’s phase III trial in erectile dysfunction has not deterred the company, but has instead encouraged it to seek approval for its medical device delivering the placebo rather than the drug as originally intended. Based in Surrey, UK, Futura Medical is developing a medical device used […]

December 10, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2019

Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy

London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […]

December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

In Depth 9 Dec 2019

As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers?

With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience. Over the last decade, big pharma has become disillusioned with neuroscience research. Eli Lilly, Amgen, Pfizer, […]

December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us